Renaissance Capital logo

ABCM News

US IPO Week Ahead: 7 IPOs squeeze in before the Thanksgiving holiday

MRVI

Updated Monday, 11/16. US IPO market activity is picking back up ahead of the Thanksgiving holiday, with seven IPOs scheduled to raise $3.6 billion in the week ahead.  Biotech research product provider Maravai LifeSciences (MRVI) plans to raise $1.3 billion at a $6.6 billion market cap. Maravai provides critical products to enable...read more

US IPO Weekly Recap: McAfee leads a 5 IPO week

MCFE

Five IPOs and 17 SPACs went public this past week. While new filing activity has slowed as the election approaches, four IPOs and four SPACs submitted initial filings. Leading security software provider McAfee (MCFE) priced slightly below the midpoint to raise $740 million at a $9.4 billion market cap. Taken private by Intel in 2011, McAfee provides...read more

UK-based research tool provider Abcam prices US IPO at $17.50

ABCM

Abcam, which sells biological reagents and tools for research, drug discovery, and diagnostics, raised $157 million by offering 8.9 million ADSs at $17.50, below the as-converted last close of $18.06 for its shares trading on the AIM (ABC). At pricing, the company raised 6% more in proceeds than anticipated and commands a fully diluted market value of $4.0 billion. Abcam...read more

UK-based research tool provider Abcam sets terms for $148 million US IPO

ABCM

Abcam, which provides biological reagents and tools for research, drug discovery, and diagnostics, announced terms for its US IPO on Monday. The Cambridge, United Kingdom-based company plans to raise $148 million by offering 8.9 million ADSs at $16.52, the as-converted last close of its shares on the AIM (ABC). At the proposed deal size, Abcam would command a fully diluted...read more